X4 Pharmaceuticals Inc. (NASDAQ:XFOR) does about 1.33M shares in volume on a normal day but saw 423127 shares change hands in Friday trading. The company now has a market cap of 114.96M USD. Its current market price is $0.98, marking an increase of 1.49% compared to the previous close of $0.97. The 52 week high reached by this stock is $2.41 whilst the lowest price level in 52 weeks is $0.65. The script in recent trading has seen the stock touch a high of $0.9996 and a low of $0.925.
X4 Pharmaceuticals Inc. (XFOR) has a 20-day trading average at $0.9990 and the current price is -59.38% off the 52-week high compared with 50.75% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.9795 and its 200-day simple moving average is $1.2667. If we look at the stock’s price movements over the week, volatility stands at 6.99%, which increases to 7.45% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 45.71 to suggest the stock is neutral.
8 analysts observing the X4 Pharmaceuticals Inc. (XFOR) stock have set the 12-month price targets for the company’s shares at between $3.00 and $7.00. The consensus objective for the share price is $4.79, suggesting that the stock has a potential upside of 79.54% over the period. The median price target is 80.4% away from the current levels at $5.00.
FactSet Research has provided data showing that 8 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 8 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on December 22, 2022 when Cantor Fitzgerald initiated the stock to “Overweight” and issued a price target of $3. Oppenheimer initiated its price target at $20.
The current price level is -2.45%, -0.41%, and -22.73% away from its SMA20, SMA50, and SMA200 respectively, with the XFOR price moving above the 50-day SMA on February 17. X4 Pharmaceuticals Inc. (XFOR) stock is up 1.02% over the week and -5.78% over the past month. Its price is -1.32% year-to-date and -40.61% over the past year.
The stock last released its quarterly earnings report for quarter ended 9/29/2022, with the company’s earnings per share (EPS) of -$0.26 above consensus estimates by $0.04. XFOR’s earnings per share are forecast to grow by 63.20% this year and 43.50% over next year.
Its 12-month price target is $5.00. To reach the target analysts have set, the stock logically needs to grow 79.54 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $3.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $7.00.
Outstanding shares total 83.21M with insiders holding 0.57% of the shares and institutional holders owning 46.47% of the company’s common stock. The company has a return on equity of -200.40%. The beta has a value of 0.54. Price to book ratio is 1.32.
According to a U.S. Securities and Exchange Commission filing, AXA Framlington Biotech Fund has added its position in X4 Pharmaceuticals Inc. (XFOR) to 3,929,336 shares, mirroring a recent increase by 2.11%. AXA Framlington Biotech Fund added 81280.0 shares of X4 Pharmaceuticals Inc. common stock bringing its total worth to about $4.05 million at the end of recent close, SEC documents show. AXA Framlington Biotech Fund isn’t the only investment manager who changed stakes and is followed by Vanguard Total Stock Market Index, which added 0.18 million shares to end up with 3,081,349 shares worth $3.17 million.
